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Summary 
Protein-protein interactions (PPIs) have a pivotal role in many biological processes 
suggesting that targeting macromolecular complexes will open new avenues for the 
design of the next generation of therapeutics. A wide range of “in silico methods” 
can be used to facilitate the design of protein-protein modulators. Among these 
methods, virtual ligand screening, protein-protein docking, structural predictions 
and druggable pocket predictions have become established techniques for hit 
discovery and optimization. In this review, we first summarize some key data about 
protein-protein interfaces and introduce some recently reported computer methods 
pertaining to the field. URLs for several recent free packages or servers are also 
provided. Then, we discuss four studies aiming at developing PPI modulators 
through the combination of in silico and in vitro screening experiments.  
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Introduction 
Protein-protein interactions (PPIs) control most biological processes and the prospect of manipulating 
macromolecular complexes, either by blocking or stabilizing molecular interactions, holds promise for 
generating novel therapeutic agents as well as tools to improve our understanding of biochemical pathways 
[1-6]. However, finding drug-like compound modulators of PPIs has long been regarded as intractable. 
Indeed, the concept was that macromolecular protein-protein complexes could only be modulated (impeded 
or stabilized) by relatively large molecules, like, for examples, heparin [7-11], peptides (e.g., aptamers) or 
(miniature) proteins [12-17] or large antibodies (as for example seen in vivo in pathological conditions 
such as Haemophilia A where antibodies usually impede macromolecular interactions [18]) or through the 
design (or lucky finding) of monoclonal antibodies that can enhance protein-protein interaction (e.g., the 
FIXa-FVIIIa interaction) [19]. Also, one of the possible reasons for slow progress with the design of drug-
like modulators of PPIs (or other targets) in academic settings is linked to the fact that screening compound 
collections to find “hits” was considered almost up to the 90’, as anything but science. Then, from around 
1985 to 1995, the concept went from deep skepticism to marginal enthusiasm while today many groups 
that were against this strategy claim that screening, whether using experimental high-throughput screening 
(HTS) methods or in silico approaches, represents an exciting paradigm in academic biological research !  
  Projects involving the development of small-molecule modulators of PPIs can clearly be 
considered at first as very risky: the interface region is usually very large, often fantasized as featureless 
and undergoing conformational changes while the biological assays to validate the effects of a small 
molecule on PPIs are usually truly difficult to design and to miniaturize for HTS studies. However, over 
the years, many research/clinical studies were pointing to the direction of targeting PPIs. For instance, 
some 10 years ago, alanine-scanning mutagenesis was used to identify what is commonly called today 
“hot-spots” (residues that contribute over 2 kcal/mol to the binding free energy) [20], suggesting that it 
may not be necessary for a small molecule to span a large part of the interface. Along the same line of 
reasoning, but after analysis of mutation data in patients (thus in vivo) and confirmation of the possible 
impact of the substitution in vitro via site directed mutagenesis, it has also been observed that naturally 
occurring mutations could impede protein-protein interaction (see for example the factor VIII-von 
Willebrand factor interaction [21] or the discoidin domain receptor 1-collagen interaction [22]), suggesting 
that a small perturbation in one specific region (i.e., most likely a hot-spot region but allosteric sites can 
also impede association) can significantly alter a macromolecular interaction, opening the door for drug-
like molecule interventions and rational design. While PPI antagonists would be very valuable in many 
disease indications, it is important to keep in mind that PPI stabilizers could also be beneficial. Indeed, 
some molecules are well-known to perform this task [23], for examples: antibodies, peptides and heparin 
(e.g., bridging effects) but drug-like molecule stabilizers or promoting protein-protein associations are less 
documented [23, 24]. In addition, when some stabilizers are identified, the mechanisms of action(s) are 
usually not fully understood (allosteric effects, bridging effects, stabilization of one partner, etc), making 
the rational design of drug-like stabilizers very difficult. 
 
  In order to identify drug-like molecules able to interfere with a protein function, several 
methodologies can be employed. While biophysical methods (NMR, crystallography, fragment-based 
approaches, etc)[25-28] and HTS experiments have all been shown efficient for hit-finding (although the 
hit rates can be low with HTS methods [29]), a major drawback with these approaches is the cost, with 
screening campaigns easily reaching hundred thousands to millions of US dollars (screening 100,000 
compounds can cost from 100,000 to 1 million US $ while solving the X-ray structure of some proteins can 
cost well over 1 million US $) [30-32]. In silico simulations can reduce the time and cost of the overall 
process in many cases (e.g., a 3D structure of the target is known or can be generated through 
 4
theading/comparative model building or some active ligands are known) [33-35]. It is also important to 
mention that in silico approaches can be relatively expensive as well, depending on the protocols and 
selected algorithms (e.g., stochastic methods are usually very CPU demanding) [36, 37]. While in silico 
strategies have been successfully applied to catalytic sites, targeting PPIs is still considered as extremely 
challenging. In fact, it may not be more challenging to target PPIs than some catalytic sites: it all depends 
on the topology, physico-chemical nature and malleability of the interface area. In fact, several molecules 
disrupting protein-protein interactions have already been reported, often through a combination of in silico-
in vitro screening strategies [1, 38-40]. These studies definitively open new avenues for therapeutic 
interventions.  
 
  Computational techniques yield useful insights into an ever-wider range of biomolecular systems 
but also suffer from limitations that will have to be addressed in the coming years. Protein three-
dimensional structures and molecular functions can be predicted in some circumstances, non-covalent 
binding of biomolecules can be understood by considering structural, thermodynamic and kinetic issues, 
and theoretical simulations of such events can be attempted. Chemoinformatics approaches combined with 
structural bioinformatics and appropriate experimental approaches are now well established and help to 
prioritize, design, analyze and rationalize experiments and ultimately can facilitate the design of new 
therapeutic compounds (Fig. 1). Drug discovery requires an integrated, multi-disciplinary approach 
considering the complexity of the task at hand. With the above data in mind, the purpose of the present 
review is to present some recent studies in which scientists were able to modulate protein-protein 
interactions through combined in silico-in vitro screening experiments. Yet, prior to discuss these 
examples, we will introduce several concepts pertaining to the field of protein-protein interactions (i.e., 
nature of the interface, prediction of residues potentially involved in protein-protein interaction) and to the 
field of chemoinformatics (i.e., druggable pockets, compound collections and virtual screening methods).  
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Protein-protein interface: a brief overview 
Proteins are usually involved in interactions with an estimated average of 5-10 protein partners [41], the 
binding site(s) with these partners may or may not overlap, illustrating the complexity ahead with regard to 
identifying, understanding and predicting protein interaction networks. In addition, different types of 
protein complexes have been observed, like homo- and hetero-complexes (i.e., the interaction occur 
between identical or non-identical chains), obligate and non-obligate complexes (a related view refers to 
interactions as transient or permanent) [42-45]. Well-known examples can be, for a permanent complex, 
the interleukin 8 homodimer (PDB code 1il8), and for a non-obligate complex, the cytochrome c 
peroxidase associated with cytochrome c (PDB code 2pcb). Depending on the types of complexes 
(permanent, transient…), the nature of the interface usually differs, from somewhat hydrophobic/aromatic 
to a mixture of hydrophobic/aromatic and polar properties [45]. Different in silico methods have been 
developed to analyze the physical properties of proteins and learn more about how these properties are 
associated with binding. Interactions at the interface are usually measured in silico in terms of accessible 
surface area, shape complementarity, molecular surface and the associated mathematical objects, Voronoi 
diagram, Delaunay tessellation, Laguerre polyhedral decomposition and α-shape [46-49]. Topographical 
information can also be determined using an algorithm based on the measurement of atomic density near 
the molecular surface [50]. Results (in term of statistics) obtained with these methods have to be taken with 
cautions since computations are usually performed on static structures. Nevertheless, such investigations 
have obviously been shedding lights on PPIs. Interfaces have been found to be either relatively flat or to 
present convex and concave shapes, indicating in these latter cases that shape-shape complementarity in 
addition to chemical complementarity can be of major importance for PPIs (just like for protein-small 
ligands). The importance of the “shape descriptor” essentially applies to homodimers, enzyme-inhibitor 
complexes and permanent heterocomplexes [51]. In some other cases, electrostatic steering plays an 
essential role and can drive the formation of an encounter complex and of the final functional complex 
[52]. In addition, analysis of packing at the interface was also performed and suggests that for homodimers, 
enzyme-inhibitor complexes and permanent heterocomplexes, the interfaces are usually well-packed [53]. 
 
  Following the discovery of hot spots [20], computer analysis of crystallized complexes has 
provided new insights about protein interfaces [54-61]. However, this topic is still an area of intense 
investigations [44, 62-68]. Yet, it has been shown that contiguous regions on a protein could form the 
signature for protein-binding, these are commonly called ‘patches’ [69]. A surface area, less than 800 Å2, 
would form a key interaction point, composed of specific amino acids, surrounded by a zone, which is 
supposed to isolate this contact zone from the solvent. This finding joins the theory of ‘O-ring’ described 
by Bogan et al. [54]. Regions surrounding the hot-spots residues are highly dense, leading to solvent 
exclusion, thereby decreasing the local dielectric constant, and enhancing electrostatic interactions [70]. 
Identification of conserved residues alone is generally not sufficient for complete and accurate prediction 
of protein-protein interfaces. The interface is rarely significantly more conserved than other surface patches 
and when an interface is among the most conserved surface patches, it tends to be part of an enzyme active 
site [71]. Thus, this structural/physico-chemical diversity renders theoretical predictions of hot-spots rather 
difficult. Interestingly, molecular dynamics simulations on sets of complexes have highlighted that few key 
interface residues generally adopt the same conformation in the unbound and bound-form of the partners 
whereas peripheral interface residues adopt a wider range of possible rotamers [72-74]. Help to investigate 
interfaces will in part come from further analysis of protein-protein complexes and unbound partners. To 
this end, databases of protein interactions are instrumental [75-89].  
  The energy of interaction between two proteins can be computed to help predict or analyze 
complexes and interfaces. Several types of scoring functions have been reported, ranging from physics-
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based methods to statistical potentials (see for example [57, 90-93]). Several tools have been proposed to 
predict binding sites, ranging from computation of the relative free energy of interaction, identification of 
hydrophobic clusters, search for planarity, protrusion, sequence similarity, phylogenetic profiling to 
solvation potentials (many free tools are listed at www.vls3d.com [94] and in Table I) [57, 93, 95-107]. It 
is still very challenging to obtain the experimental structure of protein-protein complexes but many recent 
and promising docking have been reported and should assist the process [108-124]) (see some protein-
protein docking packages in Table I and in [94]). Ranking of the proposed binding modes after protein-
docking experiments is very difficult, and therefore the scoring functions are usually supplemented with 
experimental data (i.e., concept of protein docking via hybrid approaches), like site-directed mutagenesis, 
epitope mapping or site-directed glycosylation [125, 126], yeast-two-hybrid [127], FRET/BRET [128], 
surface plasmon resonance [129] and calorimetry [130] coupled with for instance mutagenesis, SAXS 
[131], electron microscopy [132], affinity purification-mass spectrometry [133], protein microarrays [134] 
or NMR [57].   
  In some situations, it will be possible to obtain a docked model that matches with some 
experimental data and presents some “hot-spot” residues at the interface together with a so-called 
druggable pocket (see below). When such situation occurs, it should then be possible to perform in silico 
screening experiments [57, 135]. Such a project (interface unknown or not well defined) would seem very 
challenging and most likely would require the testing of a relatively large number of compounds (e.g., from 
2000 to 50,000) in vitro to increase the chance of finding hits. Yet, even these very difficult cases, the in 
silico approach may still be valuable and time/money-saving as compared to the screening of hundreds of 
thousands of compounds. Along the same line, it could be valuable to act next to the interface regions, and, 
in this case one may search for allosteric sites. However, this exercise can be extremely challenging to 
available in silico methods as the predictions and handling of allosteric sites are only possible in some rare 
cases. New methods should allow such projects to be undertaken effectively in the coming years [57, 136, 
137]. 
  The notion of druggable pocket is very important for in silico and experimental screening alike 
(Fig. 2) [138] but before commenting about binding pockets, it is important to define the terms “hot-spots” 
and druggability. Hot-spots, as mentioned above, are mainly used for protein-protein interactions but some 
authors also use “hot-spots” for residues within the binding pocket that contribute the most to ligand 
binding (i.e., affinity). The term druggability can be confusing since it does not only stand for the ability of 
a protein’s binding pocket to bind a drug-like compound with high affinity [138] but it can also refer to as 
predicting if a protein is druggable in terms of tissue distribution, number of pathways in which the target 
is involved, the number of homologues outside its family, etc [3]. In the following paragraph, we discuss  
druggability in term of pocket and not directly in term of validation/selection of a target (i.e., the two can 
be linked as if they are no pockets, the target may not be amenable to in silico-in vitro methods). Also, we 
will not use “hot-spots” for druggable pocket per se. 
Druggable pockets may not be always visible in a static 3D structure but if they do, they usually have to 
display some key structural features and physico-chemical characteristics to be considered as druggable 
and as such they tend to be different from any pocket and small cavity that are often present at a protein 
surface (i.e., a druggable pocket tends to have some specific shape, volume, content in hydrophobic 
residues, depth…)[139-143]. Here again, just like in the case of the prediction of protein-protein interfaces, 
the rules to define a pocket as druggable are not strict, although, in general, a certain volume is required 
(e.g., from about 300 to ~1000 Å3) [139, 144, 145]. Many different algorithms have been developed to 
investigate pockets, including neural network and support vector machine approaches, that can help in 
some situations but not all due to the dependence of these tools on the training set and the subjective 
definition of what is and what is not a binding pocket [144, 146-151]. Binding pockets, interfaces and local 
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geometries [152] can be analyzed and/or compared, like for instance via SitesBase [153], Cavbase [154], 
LigASite [155], SimDock [156] and sc-PDB [157] (please see a detailed list in [94]). If a druggable pocket 
overlaps with a hot-spot, then it is likely that in silico methods would succeed in identifying drug-like 
modulators for this particular PPI. The nature of the binding pocket can also help in deciding which 
docking tools is more appropriate and which scoring functions are more likely to find hits [37, 140, 158]. 
Many free and commercial tools are available to help identify and analyze these cavities [94] (Table II), 
they usually rely on geometric algorithms and/or probe matching algorithms (in average, energy-based 
approaches, i.e., probe matching, tend to perform better that purely geometry-based methods) [159]. As 
mentioned above, complex formation is accompanied in some cases by various structural changes: these 
include changes in the position of side chains, motions of the main chain or entire domains. These 
structural changes can influence the detection of druggable pockets and require special considerations (see 
below). 
  The rational behind interfering with PPIs is still under debate. For instance, some authors suggest 
that inhibiting protein association is not really possible from a thermodynamic standpoint assuming that 
protein-protein interfaces should be mostly flat [160]. This is understandable but among the many protein-
protein interactions taking place in living organisms, certainly a sizable number will present a druggable 
pocket at the interface. Moreover, we have already succeeded in blocking a rather flat interface with small 
drug-like molecules (manuscript in preparation) suggesting that additional thinking are needed before 
deciding if this mechanism is druggable or not. In order to investigate PPIs, we have analyzed about 50 
complexes obtained from two databases of experimentally determined protein-protein complexes, 
PROTCOM [85] and DOCKGROUND [86]. We, for instance, investigated the representative unbound 
collection of protein complexes recently reported by Gao et al. [86], removed antibody-protein complexes 
as well as enzyme-inhibitor complexes and focused our attention on a small set of 15 non-redundant, 
representative and diverse protein complexes. Among them, about 60-70% present with a well defined 
druggable pocket at the interface (Fig. 3). These pockets are clearly visible on the crystal structure of the 
isolated partners and are very similar in the complexes, indicating that no major structural changes are 
taking place upon complex formation and that with some experimental knowledge of the interface area and 
druggable pocket prediction algorithms, it would be possible to use in silico screening tools to target these 
interactions. Furthermore, we investigated several complexes from the bound collection [86] and noticed 
that next to the interface, druggable pockets are often present, suggesting that allosteric sites are likely to 
be present at many interfaces, definitively opening possibilities for the design of tomorrow’s new drugs 
(i.e., antagonists and stabilizers). Our identification of potential allosteric sites is in agreement with the 
investigation of interfaces recently reported by Block et al. [160] (see below). 
 
 
Virtual ligand screening: strengths and limitations 
Among the different in silico screening methods, one can usually distinguish two main virtual screening 
strategies: ligand-based screening and structure-based screening (Fig. 4). Most of these high-throughput 
tools have been recently reviewed and interested readers can find detailed information in [28, 161-171]. 
Also, several of these methods are freely available to academic groups, they have been recently listed in 
[94]. The ligand-based and structure-based approaches can be combined and fully integrated with the other 
experimental methods as shown in some recent reports [172-174] while in the case of PPIs, since in most 
cases there will not be any known ligand, the use of structure-based (SB-VLS) methods appear more 
appropriate. 
  In the ligand-based methods (similarity and substructure search, clustering, QSAR, 
pharmacophore matching or three-dimensional shape matching), the concept is to use information provided 
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by compounds that are known to bind to the desired target and to use these data to identify molecules in the 
databases with (more or less) similar properties (notion of scaffold hopping [175-178]). For structure-based 
methods (SB-VLS), it is assumed that the three-dimensional (3D) structure of the target is known either by 
X-ray crystallography or NMR experiments or predicted by homology (see comments about homology 
modeling and recent methods allowing structural prediction using this approach in [67, 179-183]). The 
principle with SB-VLS methods is to dock all the ligands (or most of the ligands if the protocol involves a 
hierarchical procedure) present in a database into the binding pocket of the selected target and evaluate the 
fit between the molecules. To perform in silico screening computations, appropriate compound collections 
are needed, often the compounds have to be transformed in 3D and some ADME/Tox (for absorption, 
distribution, metabolism excretion and toxicity) computations may have to be performed and often tuned 
according to the project (i.e., in case of PPIs, most likely the commonly used ADME/Tox parameters will 
have to be modified) (Fig. 5). As such, both the ligands and the proteins have to be prepared prior to 
running in silico computations. 
  Databases of small molecules are needed for basically all virtual screening projects. These 
compound collections (purchasable molecules, about 10 millions in total in 2007) can be obtained in 2D 
and in general in SDF format (in some cases in SMILES) from Chemical vendors. Some of these libraries 
contain only marketed drugs and/or natural products while others are for cherry picking. Many of these 
collections have been analyzed in depth these last few years [184-190] (Table III). Virtual compound 
collections can also be generated with the risk that some molecules will not be possible to synthesize 
easily. In addition, pharmaceutical companies have usually proprietary compound collections that are not 
available to academic groups. As introduced above, many purchasable compounds or virtual compounds 
may not have satisfactory ADME/Tox properties to be considered as promising drug candidates. It is then 
possible to remove from the libraries some of these molecules by computing properties such as: absorption 
prediction via computation of logP, logD, molecular weight, polar surface area (e.g., if greater than 140 Å2, 
poor intestinal absorption), number of H-bond donors-acceptors, number of rotatable bonds (see Lipinski 
rule of 5 reviewed in [191]), frequent hitters, reactive chemical groups, etc) using in silico methods ([191-
199]) (Table III). It is commonly accepted that absorption, distribution and excretion are dependent on 
similar descriptors while metabolism and toxicity are of a quite different nature and depend of numerous 
factors. Clearly all in silico ADME/Tox prediction methods (this observation also applies to in vitro and to 
animal models) should be considered with care because the human organism is an immensely complicated 
system and it is not possible at present to simulate accurately all the different events in a computer. Yet, 
these tools, whether in silico or in vitro can provide valuable information in many situations.   
  For a screening project, small molecules usually go through several in silico ADME/tox filtering 
steps in an attempt to generate a database of molecules that have physical properties and chemical 
functionality consistent with known drugs/leads/hits (i.e., we aim at keeping in the library molecules 
having characteristics, topological descriptors, physicochemical descriptors (etc), similar to those of known 
marketed drugs that are, by definition, classified as drug-like). Several suggestions have been made to 
facilitate the design of a database suitable for in silico screening experiments, interested users can find 
recommendations in the following articles [200-203]. An important concept is that compound collections 
do not need to contain millions of compounds, smaller, more focused or more diverse collections of higher 
quality can be much more appropriate for a screening campaign. For some projects, it may be necessary to 
design a database of small fragments and here also, several “recipes” have been reported [204, 205]. For 
many in silico screening experiments, the small molecules have to be in 3D, several tools are available to 
generate 3D structures of small molecules [94] while some servers already deliver the collections in 3D 
(single conformer or multi-conformer and usually ADME/Tox filtered) [206-210] (Table III). Yet, it is 
important to note that predicting 3D structures, computing charges, multiple protonation states, stereo-
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chemistries (e.g., racemic mixtures) and regio-isomeric forms (E/Z isomerism), tautomeric, and 
conformational states (multiple conformers) for large databases are challenging and obviously not always 
possible while not always needed, it usually depends on the sensitivity of the methods and algorithms used 
for the docking-scoring experiments [211-213]. 
  Recently, an in silico attempt to extract potential PPI inhibitors from compound collections has 
been reported. In that study, the authors extracted known PPI data from the literature (25 representative 
molecules were selected) and computed various descriptors (e.g., molecular shape) for each compound and 
used machine-learning methods to try to discriminate PPIs inhibitors from non-PPI inhibitors. The results, 
although preliminary, show that it is possible to enrich a collection 10-fold in PPI inhibitors with the 
consideration of only a few descriptors [214], but it remains to be seen if a database prepared along this 
line will effectively facilitate the in vitro discovery of PPIs modulators as compared to a non-PPI-filtered 
collection. 
  The target 3D structures of proteins usually need to be prepared for SB-VLS experiments. This 
step often involves the addition of hydrogen atoms and the prediction of the correct protonation state for 
the titratable residues, adding or removing water molecules, counterions, metal ions, cofactors, sugar 
molecules, removing subunits not involved in ligand binding or far from the binding site, introducing 
corrections to the tautomeric states of histidine residues and re-orientations of hydroxyl groups. Pocket 
predictions, as mentioned above, have to be performed if the zone that needs to be screened is not known 
experimentally. In the present context of structural genomics and the small number of known drug-like 
compounds interfering with protein-protein association, it is likely that SB-VLS approaches are the 
methods of choice to modulate PPIs (Fig. 5). In fact, SB-VLS methods have already been successfully 
applied to basically all types of targets (experimental structures or homology models) and biological 
mechanisms: catalytic sites [215, 216], protein-protein interaction [216, 217], protein-membrane 
interaction [218], protein-DNA interaction [219], protein-RNA interaction [220], protein-heparin 
interaction [221]. In addition, these computer methods start to be used on extremely complex mechanisms 
such as protein-misfolding diseases [222]. Yet, in the case of PPIs, it is likely that difficulties will arise on 
some targets due to possible flexibility of the binding regions and special considerations will have to be 
taken for this target class (see below). Assuming that the appropriate receptor 3D structure is available, a 
primary challenge in hit discovery via SB-VLS is to predict both ligand orientation and binding affinity; 
the former is often referred to as ‘molecular docking’ while the latter is referred to as ‘scoring’ (Table IV). 
Docking protocols can be described as a combination of two components: a search strategy and a simple 
scoring/fitting function to assess the poses prior to the real scoring step. The search algorithm should 
generate an optimum number of conformations for the ligands and of poses that should include the 
experimentally determined binding mode. The complexity of molecular docking implies several 
approximations, from rigid body docking (where both partners are treated as rigid but “flexibility” can be 
generated prior to docking), to (pseudo)-flexible ligand docking (where the receptor is held rigid and the 
ligand is partially flexible) to flexible docking (where both receptor and ligand flexibility are considered). 
Algorithms dealing with flexibility from the ligand side can be divided in three types, namely (a) (pseudo-) 
systematic (e.g., incremental construction algorithms; database methods with libraries containing pre-
generated conformations for each molecules), (b) stochastic or random algorithms (e.g., Monte Carlo 
methods, Tabu search/evolutionary algorithms, they make random changes on some variables and usually 
require multiple independent runs), and (c) deterministic searches or simulation methods (e.g., energy 
minimization and molecular dynamics) [223]. Many free tools performing such tasks are listed in a recent 
review [94] (see also Table IV).   
  Generating a broad range of binding modes is ineffective without a model to rank each 
conformation that is both accurate and efficient/fast. The scoring functions commonly used are said to be: 
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force-field based, empirical and knowledge-based [224-227] while consensus scoring can provide 
interesting insights/results [228] and that in some situations, quantum mechanics can improve the results 
[229]. It is however important to note that the more accurate the computations the more sensitive they 
become to small errors in some parameters (e.g., partial charges) and in the position of the ligands in the 
binding pocket. In general, some scoring functions perform well on some target classes but not on others. 
There are no clearly defined rules to predict a priori which scoring functions will be successful on a given 
target although the nature of the binding pocket can give some insights [37] since it governs the overall 
shape, size and physico-chemical nature of the ligands. A strong emphasis is now being put on post-
processing strategies rather than on designing more accurate generic scoring functions. Post-processing can 
involve consensus docking and/or scoring [161, 228] and tools that facilitate the interactive analysis of the 
docked molecules (e.g., Post-Dock [230]). Hierarchical protocols that, for instance, involve rigid-body 
docking followed by flexible ligand docking and possible rescoring using relative free energy computations 
have been proposed [37, 135, 231-233]. Another way of conceiving post-processing (or pre-processing) is 
through the notion of fingerprint [234, 235]. In this situation, a 1D binary fingerprint representation of the 
intermolecular interactions in a 3D protein-ligand complex is computed. For example, amino acids in 
contact with the ligand are represented as a bitstring with each bit switched to on or off depending whether 
it is involved in a contact, the contact is with the main chain or the side chains of the protein, and if the 
interaction is polar, apolar or involve hydrogen-bond donors/acceptors. This approach is implemented in 
the SIFt package that uses 7 bits for each binding site residue representing 7 different types of interactions 
[234] but other methods have also been developed like FLAP [235]. The whole interaction fingerprint is 
then constructed by concatenating the bit strings for each binding site residue. Fingerprints can be used for 
comparing ligands and learn about target specificity, for ranking and for the construction of focused 
libraries. These methods are promising in the context of screening large compound collections with 
relatively modest computer power but additional investigations are needed to validate the superiority of 
these programs as compared to for instance packages build on decades of physics-based developments.  
 
  We and many other research groups have performed comparative studies and the overall picture 
indicates that no one docking method currently outperforms others across diverse protein targets (see 
below). In other words, some docking/scoring approaches are very efficient on some targets but not on 
others [167]. What is generally observed is that docking methods are able to reproduce the experimental 
poses as seen after comparisons with crystallographic studies but that the scoring does not always allow 
for the selection of the right binding mode and does have problems with ranking, leading to many high-
scoring false positives, thereby lowering enrichment rates. These observations indirectly point to the 
concept that important information are present in the binding pocket but that they are not appropriately 
considered with the current docking/scoring methods. In our opinion, structural and physico-chemical 
properties have to be taken into account during the docking and the scoring steps to improve the process 
and most likely existing methods are already at hand to perform these tasks. We advocate that now, 
studies should be undertaken to correlate pocket descriptors with the docking/scoring algorithms. This 
represents an area of intense investigation in our group (manuscript in preparation) that remains extremely 
challenging. 
 
  Several metrics are commonly used to analyze hit lists including calculation of enrichment factor, 
hit rate and area under the receiver operating characteristic curve (ROC). The enrichment factor or rate is 
the increase in the proportion of hits found in any given sample of compounds, compared with the 
proportion expected from a random sample [236]. This value is often used to benchmark in silico methods. 
If we imagine having 100 actives in a collection of 100,000 compounds, the chance of picking one active at 
 11
any toss should be 100/100,000 thus 0.001. If we generate a list of 1000 molecules at random, we should 
have in theory, 0.001 x 1000 = 1 active. Now, if a list of 1000 molecules is proposed after in silico 
screening and that 10 binders are found experimentally while we know that we have a total of 100 binders 
in our collection, then the enrichment factor at that point (1% of the database, i.e., our list of 1000 
molecules) equal 10, which is the number of binders found divided by the number of known binders 
expected from random selection (here equal to 1). EF is equal to: {found binders/number of molecules in 
the short list selected in silico}/{total number of binders/total number of compound in the collection}. In 
practice, achieving a good enrichment rate of active compounds in the chosen subset is more important 
than predicting the exact binding affinity of individual compounds, this can be attempted at a later stage. 
For hit rate, if we imagine that we test experimentally 50 molecules and, that among them, 7 are bioactive 
compounds, then the hit rate = 14% (i.e., 7/50 x 100). ROC curve and area under the ROC curve can also 
be used to assess screening studies in addition to or instead of EF [237]. Yet, Truchon and Bayly suggest 
that none of the methods used so far are really appropriate to evaluate in silico screening and have recently 
derived new mathematical formulas [238]. It will be interesting to see in the future, if one can really 
improve the understanding of in silico screening procedures by using these new equations. Along the same 
line but concerning the evaluation of docked poses, the accuracy is most of the time assessed by computing 
the RMS deviation between the predicted pose and the crystal structure. This approach is sometimes 
misleading and several authors have proposed to evaluate the presence of key interactions between the 
docked ligands and the protein versus the ones present in the crystal structure. One method of this type has 
been coined IBAC, for Interactions-Based Accuracy Classification, it highlights that in a number of cases, 
there are important discrepancies between IBAC and RMSD assessments. The suggestion is that IBAC-like 
evaluations are more meaningful to measure docking accuracy that RMS deviation [239].  
  Many benchmarking studies have been performed these last few years in an attempt to evaluate 
the performance of the diverse in silico screening methods/protocols [240]. Yet, validation of a method is 
extremely complex and subject to errors. A compound collection may not be proper to assess a method 
(e.g., too small, the actives can be very different from the others and be easily identified…), the 
docking/scoring parameters are optimized in some studies while they are not in some others making 
comparisons relatively unfair. The main message from these studies is that some packages are successful 
on some targets while fail on others but the reasons for success and failure are unclear because of the 
complex interplay among the many parameters acting on the docking and scoring steps (see for instance 
[167, 168]). Another point that we noticed with regard to in silico screening studies is the race for “hit 
rate”, something that could be called “over hit rate”. More and more studies report very high hit rates that 
do not reflect the actual strengths and limitations of in silico screening methods. For instance, SB-VLS 
methods carried out on a well-known pocket for which many co-crystal structures are known (protein with 
drug-like ligands co-crystallized, not peptides) can yield a hit rate of 50% or more. This gives the 
impression that studies with hit rate of 1% or less have failed. However, in these latter cases, it could be 
that the binding pocket is not well-defined, that it is filled with water molecules, that several amino acid 
side chains could be flexible and that co-crystals of the target with a drug-like ligand are not available. 
Also, the final selection is usually perform through visual inspections and authors may want to take the risk 
of selecting compounds that have little chance of binding as seen on the computer screen but that are 
originals and presenting with interesting scaffolds. Thus, screening more molecules with an extra list of 
risky compounds will most of the time damage hit rates but could be very valuable from a biological 
standpoint. In all cases, a hit rate of 0.5% or less as obtained after in silico computations could still be 
interesting as compared to published HTS hit rates that can easily be around 0.01% or less. Thus, hit rates 
have to be examined with care.  
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  As mentioned above, a major problem with some targets is due to flexibility (or plasticity or 
malleability) in the area of the interface [241]. Indeed, with regard to protein-protein complexes, only about 
one third can be docked without considerations of induced conformational changes [242], further 
highlighting the need of addressing this issue. The inadequacies or limitations of some experimental 
structures can be overcome in some cases by using simulation methods (e.g, molecular dynamics, normal 
mode analysis, Gaussian network models, Monte Carlo simulations) [243-245] (Fig. 6). Flexible receptor-
flexible ligand methods suited for in silico screening experiments and protocols are emerging (see for 
example [180, 246-251]), but clear successes are still missing because flexibility, if not properly treated, 
can increase the “noise” instead of facilitating identification of relevant hits. The first approach to try to 
address the flexibility problem has been the use soft potentials, where some atom overlaps are tolerated 
[216]. Another way is to dock on multiple structures (experimental or simulated) of the receptor. The 
ultimate approach would be to explicitly consider protein and ligand flexibility during docking. Yet, this 
latter approach is very computationally demanding and, for the time being, basically no packages are able 
to address the problem efficiently. The difficulties of performing docking against multiple receptor 
conformations lie with how to deal with the ranked lists since for each structure of the receptor, the 
docking/scoring procedure can propose over 1000 likely molecules. If computations are performed on 3 
structures, one may have a list of 3000 molecules to test experimentally with possibly very few consensus 
compounds. The merge-and-shrink procedure has been recently proposed to address this problem [248]. 
With this approach, for each compound, the best rank -not the best score- is kept. This was shown efficient 
on some targets but, in general, to use this approach, one needs known actives to test the protocol and 
calibrate the computations. The merge-and-shrink protocol or the consensus approach [37] can be efficient 
in some cases or dilute the correct results for some targets. As such, much work is needed to address this 
difficult question of flexibility from the receptor side. Interestingly, a recent molecular dynamics study 
investigating transient pockets on protein surfaces directly located at the interfaces has been reported [252]. 
The authors investigated Bcl-xL, IL-2 and MDM2 and propose a new pocket detection protocol. They 
observed that the native inhibitor-binding pocket was partly present in the unbound proteins. They 
performed 10 ns molecular dynamics simulations and scanned, on many structural snapshots collected 
along the trajectory, the surface of the proteins, in search of transient or more permanent cavities. They 
noticed that some cavities were opening up within 2.5 ps and that most of them appeared multiple times. In 
the druggable region, they noticed that pockets of similar size as compared with the experimental structures 
in complex with the ligand could be generated. Docking was successfully performed into these transient 
pockets, suggesting that this protocol is viable to study protein interfaces with the goal of designing 
antagonists and possibly stabilizers. An interesting point noted by Luque and Freire about catalytic sites is 
that these regions appear to have a dual nature characterized by regions of high stability and regions of high 
flexibility [253]. Analysis of pockets at the interfaces or near the interfaces is required to confirm this 
observation for PPIs. 
 
Case studies 
PPIs are challenging but attractive targets for small chemical drugs. By focusing on PPIs, the number of 
latent and novel drug targets can be expected to increase dramatically. This is because the size of the 
human interactome is much larger than that of the human proteome. With a human genome coding for 
about 25,000-40,000 proteins, the size of the interactome is estimated to be around 250,000 based on 
extrapolation from the yeast interactome. However, for the time being, the number of PPIs registered in the 
public interactome database is limited to about 40,000, suggesting that many interactions have yet to be 
discovered [254-257].  
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  Several protein-protein interactions have been successfully targeted using chemistry-in silico-in 
vitro screening approaches (and other biophysical methods such X-ray crystallography [258, 259] or NMR 
spectroscopy [26, 27, 30, 260]) and have been extensively reviewed these last few years [1, 38-40]. Well 
documented examples include, the Bcl-xL-BH3 protein-protein interaction (cancer, extended compounds 
mimic the BH3 alpha-helical structure, difficulties come from the flexibility of some regions of the 
receptor structure, large binding groove) [261], inhibitors of the p53-MDM2 interaction (cancer, relatively 
small pocket on MDM2, the compounds have to mimic an alpha-helix from p53, it does not seem that 
important structural changes occur in the binding pocket) [262], modulation of the Keap1 protein-protein 
interaction (application in, for example, cancer, Parkinson’s disease, relatively compact and exposed 
pocket, somewhat similar to MDM2, the pocket binds to a loop-like structure) [263], the BIR 3 domain of 
XIAP (cancer, not very pronounced binding groove binding a somewhat extended amino-acid segment 
from the other protein partner) [264, 265], inhibitors of the IL-2alpha receptor-IL-2 interaction 
(immunosuppressive agents, not very pronounced binding groove on IL-2 undergoing conformational 
changes, this region interacts with a somewhat extended amino-acid segment from the receptor) [266, 267], 
the G protein-coupled receptors (cancer among others, somewhat narrow binding pocket, in silico 
screening usually performed on homology models of not very high “resolution” but integrating numerous 
ligand-based results biasing the docking experiments and thereby usually leading to relatively high hit rate) 
[268-271] and the Arf-GDP-Sec7-BFA system, an example of uncompetitive interfacial inhibition in which 
a drug takes advantage of transient structural conditions created by the macromolecular complex 
(molecular mechanisms difficult to handle with in silico approaches) [272]. In the following, we decided to 
focus on four recent studies combining in silico-in vitro screening that illustrate different strategies and 
types of PPIs. 
 
Stat3 
Proteins of the STAT family are activated in response to cytokines and growth factors. They promote 
proliferation, survival and many other biological processes [273]. Upon tyrosine phosphorylation, dimers 
of STATs form between two monomers and they translocate to the nucleus and bind to specific DNA-
response elements in the promoters of target genes to finally induce gene expression. Aberrant activity of 
one of the member, Stat3, contributes to carcinogenesis and tumor progression. A critical step in STAT 
activation is the dimerization process. This step relies on the reciprocal binding of the SH2 domain of one 
monomer to the PpYLKTK sequence of the other Stat3 monomer. The crystal structure of the Stat3 
homodimer has been reported [274] and used for in silico screening studies in order to search for potential 
disruptors of the Stat3-Stat3 dimer formation [275-277] (Fig. 7). 
  In the study of Siddiquee et al., [275], the virtual screening was performed with GLIDE [278] and 
a compound collection of about 155,000 molecules (prepared with LigPrep) obtained from the NCI’s 
chemical libraries (compound 3D structures generated by Corina). One compound was found to disrupt 
Stat3-Stat3 complex formation in vitro and intact cells (total number of compounds tested experimentally 
not clearly stated). In the study of Song et al. [277], the same X-ray structure was used and a chemical 
database containing compounds from Sigma-Aldrich, Merck Index, Ryan Scientific and the NCI was used 
initially. The four databases offered a final collection of about 429,000 organic molecules (compounds in 
3D generated by Corina). The in silico screening was performed with DOCK and the top 10% scored 
compounds from each database were extracted and re-score with X-SCORE [279, 280]. Of the best-scored 
200 compounds, 100 molecules were tested experimentally and one molecule showed remarkable 
inhibition of Stat3 dimerization. From an in silico standpoint, the hit rates can be considered as low while 
from a biological standpoint, these studies can be considered as very successful. Definitively, the pocket 
tends to be relatively flat, contain a mixture of hydrophobic/aromatic and charged residues and the region 
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could be flexible (e.g., side chains or main chain) making the docking/scoring difficult (a short and 
extended peptide segment from the other monomer fits in the pocket and it is thus not an helix as often 
believed, not all protein interactions involve helices from one partner and a groove in the other partner). 
Also, the lack of small molecule co-crystallized in the binding pocket does not allow for pose assessment, 
ligand-based pre-screening and direct calibration of the scoring function according to known binders. 
These studies reflect a likely situation for most in silico screening projects targeting PPIs. It is interesting to 
note that one package, often considered as one of the best in several benchmark studies, GLIDE, does not 
perform better than DOCK [281], a program reported to be efficient on some targets but in average less 
efficient than GLIDE [158]. Of course, direct comparison cannot be perform in this way because the 
compound collections used are different, but this still illustrates (as suggested by most authors of 
benchmarking studies) that, although evaluation/comparison studies of in silico tools are of outmost 
importance, one should take the information with cautions. Stat3 is a difficult target and in this case, it 
seems reasonable to test more molecules experimentally. 
 
Antitrypsin polymerization 
α1-antitrypsin is the archetypal member of the serine proteinase inhibitor or serpin superfamily. Most 
individuals carry a normal allele but 4% of the Northern European population are heterozygous for the 
severe Z deficiency variant (this translates to a Glu342Lys substitution and subsequent perturbations of 
secondary structure elements and of the mobile reactive center loop). The resulting unstable intermediate 
molecules then link to form loop-sheet polymers in which the reactive loop of one molecule inserts as 
strand 4 of the so-called β-sheet A of another α1-antitrypsin molecule. It is the accumulation of polymers 
that predisposes the Z α1-antitrypsin homozygote to hepatitis, cirrhosis and hepatocellular carcinoma. 
Other mutations in other serpins also lead to polymer formation leading to thrombosis, angioedema, 
emphysema or familial encephalopathy [282, 283]. With regard to α1-antitrypsin deficiency, the only 
curative treatment available today is liver transplantation. Recently, Mallya et al. [284] have performed 
SB-VLS computations with the ICM package against a non-redundant library of about 1.2 million 
commercial drug-like compounds in a hydrophobic pocket present in this serpin but somewhat remote from 
this abnormal protein-protein interaction site (Fig. 8). An initial screen was performed on the crystal 
structure of α1-antitrypsin (PDB code 1qlp) [285] but none of the nominated compounds were effective in 
impeding polymerization. It should be noted that the pocket is challenging: it is located in a flexible region 
and can be considered as an allosteric cavity. Amino acid side chain simulation was performed to identify 
the most flexible residues lining the cavity and one Asn residue was found to be very flexible. A low 
energy conformation for this residue was generated through Monte Carlo simulation. SB-VLS was 
performed again and 68 compounds were selected for further characterization in vitro. One compound 
completely blocked polymerization while another one presented with interesting activity as it allowed the 
formation of only dimeric structures. Ligand-induced changes were then modeled for these 2 best 
compounds prior to an additional round of SB-VLS experiments. These changes were achieved by 
performing internal coordinate Monte Carlo side chain simulations in the presence of each ligand in its 
predicted binding pose. Nineteen extra compounds were selected after re-docking on this modified receptor 
structure, 10 of them were structurally similar to the original two active compounds, suggesting that ligand-
based approaches could also have been performed instead of docking-scoring. Some of these molecules 
were as active as the best molecule identified in the previous screen. Thus, one compound was found with 
the desired biological activity, opening new ways to block polymer formation and strategies to block 
protein-protein interaction in the serpin superfamily (i.e., yet the compound appears to be specific of α1-
antitrypsin and does not act on other members of the family). Many diseases are characterized by protein 
misfolding, aggregation and polymer formation. In general, drug-like molecules able to interfere with this 
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process are obtained after HTS, like for examples, for expanded polyglutamine proteins, PrP or tau [222]. It 
is thus remarkable to be able to use SB-VLS approaches against these complex mechanisms. 
 
β-Catenin-T-cell factor complex 
β-Catenin is a protein with multiple functions that binds to T-cell factor (Tcf) and activates transcription of 
proteins that regulate the cell cycle. Disruption of this interaction is considered to be a valid anticancer 
strategy. The complex between β-Catenin and Tcf is characterized by an unusually large interface with a 
binding constant Kd ~ 10 nM. β-Catenin is a superhelix with a large and shallow positively charged group 
and the N-terminal residues of Tcf bind along this groove. Virtual ligand screening was performed by 
Trosset et al. [286] with FLO_QXP package (4 amino acid side chains were allowed to move during the 
docking) using an ADME/Tox filtered library from the Pharmacia and Upjohn collection (initial size, 
90,000 molecules and 17,000 after filtering). Visual inspection of the top ranking 3000 compounds led to 
the selection of 42 candidates and finally 22 molecules were tested using NMR WaterLOGSY and 
isothermal calorimetry experiments leading to 3 confirmed hits and a very high hit rate of 14% given the 
context and lack of information about the pocket (i.e., the exact binding mode is not yet known nor if the 
compounds really bind to the predicted pocket). The β-Catenin-Tc3 crystal structure was used for the study 
(PDB code 1g3j) [287], 6 pockets were predicted at the surface of β-Catenin and one area, around residue 
Lys435-Arg469 contained several clefts that could potentially anchor a small molecule (this region 
interacts with a loop and strands from Tcf) (Fig. 9).  The authors comment on the obtained hit rate and 
clearly mentioned that hit rates are not the most critical parameters, rather, the key point is to find active 
compounds in a reasonable amount of time and reduced cost as compared to massive HTS campaigns.  
 
Plant H
+
 ATPase-14-3-3 protein complex 
Recently Block et al. [160] have been trying to design protein-protein stabilizers, arguing that it could be 
easier from a thermodynamic standpoint than finding antagonists. They also suggested that to find PPI 
antagonists via in silico approaches, it is necessary to identify a druggable pocket at the interface, a 
situation that is unlikely to occur. These authors investigated about 200 complexes and found relatively 
frequently a cavity, close to the interface but not at the interface, suggesting that these sites could be 
interesting allosteric sites. From our initial investigation of experimental complexes, we, to the opposite, 
find that a druggable pocket is very often present at the interface although we also noticed cavities near the 
interface. In order to carry out a proof of concept study, Block et al. [160] decided to search stabilizers of 
the interaction between plant H+-ATPase and 14-3-3 protein. This interaction is boosted by a fungal 
phytotoxin named Fusicoccin. This small but relatively complex molecule is an herbicide with applications 
in the agrochemical industry. Yet, it is difficult to synthesize and since even minor chemical modification 
impairs its biological activity and its potency to stabilize the H+-ATPase-14-3-3 complex, finding new 
chemicals to stabilize this interaction was judged interesting. SB-VLS investigations were performed, to 
both, find stabilizers of this system and serve as a proof of concept. The experimental structure of the 14-3-
3 protein (PDB code 1o9f) [288] is known, this structure contains the co-crystallize Fusicoccin and a short 
peptide that mimics the ATPase (Fig. 10). The pocket is localized next to one residue of the ATPase 
peptide and contains four water molecules. Virtual ligand screening was performed using a compound 
collection of about 2 million compounds that was downsized after some filtering steps (e.g., only molecules 
with up to 6 rotatable bonds, molecular mass between 250 and 500 Da and some other 3D pharmacophore 
filtering methods), to about 160,000 molecules. These ones were docked with FLEXX, GOLD and 
AutoDock and a post-processing step was then performed according to a pharmacophore hypothesis and 
visual inspection. Seventeen compounds were selected for in vitro testing (surface plasmon resonance) and 
none were found to be efficient in stabilizing the complex.  
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The authors had to face many difficulties in that study. First, the binding pocket is possibly flexible, it may 
be different when the complete ATPase is present and it contains water molecules. It is likely that to design 
protein-protein stabilizers with in silico approaches, an experimental structure of the complex and 
simulations are required and that more compounds would need to be tested. In contrast, it seems possible to 
design PPI inhibitors even if one structure from only one partner is available, a situation that is more 
probable at present. Furthermore, while Block et al. [160] suggest that blocking protein-protein interaction 
should not be really feasible in many cases because of thermodynamic considerations, it does seem that 
designing stabilizers is even more challenging and most likely equally difficult with regard to energetics. 
Also, the small compound will have to carry out a very difficult mechanistic task (e.g., stabilize one 
structure, stabilize the interface, bridge the 2 partners), and, when screening such an exosite next to the 
interface region, it cannot be known, a priori, if the small molecule will induce some structural changes that 
stabilize or impede the interaction. 
 
  The need of stabilizers is well documented in a wide range of diseases known as amyloidoses. 
These are also known as protein misfolding diseases since in all cases, a protein normally soluble, becomes 
insoluble. The situation usually involved some conformational changes, partial unfolding, and protein-
protein interaction. About 20 proteins have been related to different forms of amyloidosis, the only 
common characteristic shared by many of these molecules is their high content in β-structure [289]. The 
concept of stabilizing a protein complex is clearly of interest although extremely challenging and involving 
many different underlying mechanisms. For example, stabilization by small molecules was achieved for the 
transthyretin protein (TTR)[290]. TTR is composed of four identical subunits (homotetrameric protein), 
each monomer is organized as two sheets of four β-strands. Two monomers associate and the tetramer 
seems to results from the association of two dimers, leading to a central channel in the protein. This one is 
mainly hydrophobic and can accommodate two thyroxine molecules. TTR can aggregate, in this case 
tetramer dissociation must occur prior to aggregation and fibril formation. Some small molecules that bind 
in the thyroxine-binding channel seem to favor the stabilization of the native tetrameric conformation of 
TTR and may inhibit the formation of the amyloidogenic intermediate species that lead to amyloid [291-
294]. Along the same line and concept of stabilization, superoxide dismutase 1 (SOD1), like transthyretin, 
can undergo subunit dissociation and aggregation as a result of mutations. SOD1 is a homodimer that 
displays a small binding pocket at the interface between the two monomers. The structure was screened in 
silico using the Glide package, 100 molecules were selected after screening several commercial databases 
and 15 compounds apparently stabilized the system, indicating that stabilizers can be obtained using SB-
VLS methods [295]. Yet, in this case, the pocket is clearly defined at the interface and does not seem to be 
an allosteric cavity, the small compounds appear to glue the two monomers, suggesting that an 
experimental structure of the entire system was required. 
 
 
Conclusions and outlook 
In spite of present limitations, available in silico screening methods can really contribute to the drug 
discovery process. Appropriate combination/integration of SB-VLS/ligand-based screening and medium to 
HTS approaches should thus play a major role in the coming years and hopefully contribute to the 
eradication of complex diseases. A very recent investigation on the HIV-1-Nef complex illustrates further 
this view [296]. We have noted that in silico methods are now established as a powerful alternative and 
complement to experimental HTS and that they allow for the identification of novel hits with novel 
chemotypes. Yet SB-VLS methods are complex and as such, a thorough knowledge of the programs, 
protocols (e.g., multi-step, consensus scoring) is in general a requirement for success in any drug discovery 
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project. In spite of these strengths, several aspects have to be improved, like the scoring step and a better 
handling of flexibility, a point that could be critical to the design of PPI modulators. PPIs are usually 
considered difficult but may in fact be druggable. Hot-spots can be probed and in some cases predicted 
with combined experimental-in silico methods while druggable pockets in the region of the interface can be 
simulated. The difficulties that are still present to design PPI modulators can be divided into two different 
categories: (a) appropriate chemical space and (b) right protocol. For category “a”, difficulties with finding 
PPIs modulators can be due to the fact that appropriate lead compounds may not be present in the libraries,  
suggesting that it will be necessary to explore new areas of the chemical space. Another reason for the 
difficulties with PPIs (b) could be that we do not have the right protocols to properly handle this task, and 
some of the examples discussed in this review support this hypothesis. We have seen that a major 
bottleneck in some virtual screening projects is that the conformation of the target protein as found in a 
crystal structure or in theoretical models, be it bound within a macromolecular complex or unbound (apo 
form), may not be truly representative of the dominant conformation that will bind to the small drug-like 
ligands. Introduction of flexibility on the receptor side during high-throughput docking computations 
remain a major problem with no simple or single solutions. Indeed, incorporation of the receptor flexibility 
is a formidable challenge. Flap motion, side-chain movements, rotation of subdomains and movement of 
some secondary structure elements (i.e., helices) are well-documented [297, 298]. However, prediction of 
these movements is extremely difficult in the context of high-throughput ligand docking. There are also 
other types of flexibility, ranging from Gln/Asn O/N re-orientation upon or prior to ligand binding to loop 
flexibility that are also very difficult to handle. Water molecules, cofactors and metal ions can also be 
troublesome. There is room for improvements in the scoring field and possibly better scoring according to 
the nature of the binding pocket seem feasible. Furthermore, finding the right balance polar and non-polar 
interactions and better accounting of solvation and entropy should be possible. It is also reasonable to think 
that a deeper understanding of the existing tools will enhance their possibilities. Several examples of 
successful modulation of PPIs via combination of in silico-in vitro screening have been presented and it is 
clear that new success stories will be reported in a near future. While the existing in silico methods can 
address some PPIs, it seems also likely that given our lack of knowledge about these interactions, more 
compounds should be tested experimentally after in silico screening as compared to for instance catalytic 
sites. Although it is often mentioned that PPIs can only be addressed efficiently via NMR and fragment-
based approaches, we believe, after reviewing the literature, analysis of our own results and as we witness 
rapid methodological progresses in the field of computational biology and chemistry, that existing in silico 
tools can already perform such a task but that new protocols will have to be designed. In the examples 
presented here, in most cases, the hit rates from an in silico perspective are not as good as the ones obtained 
on catalytic sites, a situation that is somewhat expected. Yet, from a biological standpoint, these studies 
have usually identified very interesting molecules. Overall, in the future, we should get a better knowledge 
of what organic structural moieties are privileged or preferred at PPI sites and ultimately, we should 
succeed through targeting PPIs to develop the next generation of therapeutics. By merging the know-how 
of medicinal chemistry with the new technologies and better knowledge of diseases, by learning from 
failures and through efforts and tenacity, major accomplishments should be obtained for this target class in 
a near future. 
 
 
Acknowledgments 
Supports from the Inserm institute and Inserm-Transfert are greatly appreciated.  
 
 18
Table I: Examples of recently reported tools to predict hot-spots, analyze interfaces and for protein-
protein docking 
 
URLs Short summary Ref. 
http://www.molsoft.com/oda.cgi ODA (Optimal Docking Areas) is a method to predict 
protein-protein interaction sites on protein surfaces. It 
identifies optimal surface patches with the lowest 
docking desolvation energy values 
[96] 
http://www.bioinformatics.leeds.ac.uk/ppi_pred/ PPI-PRED can be used for protein-protein binding site 
prediction and DNA binding site prediction 
[299] 
http://www.bioinformatics.sussex.ac.uk/SHARP2 SHARP² predicts the location of protein interaction 
sites on the surface of the 3D structure of a protein 
[300] 
http://crick.mbu.iisc.ernet.in/~PIC 
 
PIC: Protein Interactions Calculator 
 
[100] 
 
http://pfp.technion.ac.il Patch Finder Plus (PFplus): a web server for 
extracting and displaying positive electrostatic patches 
on protein surfaces 
[101] 
 
http://bip.weizmann.ac.il/promate ProMateus: protein binding site analysis 
 
[103] 
 
http://3D-partner.life.nctu.edu.tw 3D-partner: a web server to infer interacting partners 
and binding models 
 
[104] 
 
http://sage.csb.yale.edu/sitefinder3d 
 
siteFiNDER3D: a web-based tool for predicting the 
location of functional sites in proteins 
[105] 
 
http://structure.pitt.edu/servers/fastcontact/ 
 
FastContact: a free energy scoring tool for protein-
protein complex structures 
[93] 
 
http://vakser.bioinformatics.ku.edu/resources/gra
mm/grammx 
Gramm: Tools for protein-protein docking  
GrammX: web interface of Gramm 
[301] 
http://bioinfo3d.cs.tau.ac.il/ Protein docking tools (PatchDock) and related tools. 
PatchDock, webserver for macromolecules and small 
molecules docking based on shape complementarity 
criteria 
[120, 302] 
http://mmb.pcb.ub.es/PyDock/ 
 
PyDock:  tool for protein-protein docking  [114] 
http://nrc.bu.edu/cluster/ ClusPro: protein-protein docking webserver using 3 
docking programs - DOT, ZDOCK, GRAMM 
[303] 
http://www.nmr.chem.uu.nl/haddock/ HADDOCK software: models any kinds of 
biomolecular complexes and multi-component (N > 2) 
systems.  
[117, 304] 
http://structure.bu.edu/index.html PIPER: An FFT-Based Protein Docking Program 
with Pairwise Potentials 
[305] 
http://dags.stanford.edu/InSite/software.html InSite: a computational software that integrates high-
throughput protein and sequence data to infer the 
specific binding regions of interacting protein pairs 
[306] 
 
 
 
 
 
 
 
 
 
 19
 
 
 
Table II: Some free tools to predict druggable pockets 
 
 
 
 
URLs Short summary Ref. 
http://www.bioinformatics.leeds.ac.uk/qsitefinder 
http://www.bioinformatics.leeds.ac.uk/pocketfinder 
Server to predict binding sites, Q-site and Pocketfinder  [307] 
http://interface.bioc.columbia.edu/screen SCREEN: Server to predict binding site  [159] 
http://medock.csie.ntu.edu.tw/ MEDock: Online tool to define binding site  [308] 
http://bioserv.rpbs.jussieu.fr/Help/FAFDrugs.html PASS: Pocket detection method  [206, 309] 
http://firedb.bioinfo.cnio.es/Php/FireStar.php FireStar: small molecule binding site prediction 
 
[310] 
 
http://www.modlab.de PocketPicker: tool to predict binding pocket, has to be used 
with PyMol 
 
[311] 
http://proline.physics.iisc.ernet.in/pocketdepth 
 
PocketDepth: tool to predict binding pocket [312] 
http://bioinformatics.cm-uj.krakow.pl/activesite Online recognition of a ligation site in a protein molecule 
based on the fuzzy-oil-drop model 
[313] 
http://scoppi.biotec.tu-dresden.de/pocket/ LIGSITEcsc: a web server for identification of pockets on 
protein surfaces 
[314] 
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Table III: Some free compound collections, 2D-to-3D methods and ADME/Tox tools 
 
URLs Short summary Ref. 
http://chembank.med.harvard.edu 
  
ChemBank: Free collections and utilities, known drugs, 
many annotated molecules, molecules with druglike 
and non-druglike properties 
none 
http://pubchem.ncbi.nlm.nih.gov/ PubChem: An information resource linking chemistry 
and biology 
none 
http://www.chemnet.com/ 
 
Chemical suppliers and collections none 
http://www.rxlist.com/02top.htm Top 200 prescriptions in 2002 (structure and name of 
the compounds) 
none 
http://www.bioscreening.com/compound_libraries.htm Web directory about compound collections and many 
related links, database search 
none 
http://cdb.ics.uci.edu/CHEM/Web/ ChemDB: Free collections and utilities such as 
similarity search 
none 
http://bioserv.rpbs.jussieu.fr/Help/FAFDrugs.html 
(see also:  http://www.vls3d.com/) 
FAF-Drugs: Free collections in 3D (and ADME/tox) 
and utilities  
[206] 
http://zinc.docking.org  ZINC: Free collections in 3D (and  ADME/tox) [208] 
http://bioweb.ucr.edu/ChemMine  ChemMine: Free collections and similarity search 
utilities  
[209] 
http://redpoll.pharmacy.ualberta.ca/drugbank/ DrugBank: Numerous data about drugs and targets 
including drugs already in use  
[210] 
http://dtp.nci.nih.gov/index.html The US National Cancer Institute collections including 
natural products  
none 
http://www.emolecules.com/ With eMolecules you can draw your chemical structure 
and instantly search millions of molecules from across 
the Web and from chemical suppliers worldwide 
none 
http://chem.sis.nlm.nih.gov/chemidplus/ ChemID Plus: chemical name, physical and 
toxicological properties 
none 
http://llama.med.harvard.edu/~jklekota/QueryChem.html QueryChem: searches public databases using text and 
structure 
[315] 
http://relibase.ebi.ac.uk 2D to 3D conversion [316] 
http://www.molecular-
networks.com/online_demos/corina_demo.html 
Corina: 2D to 3D conversion none 
http://www.eyesopen.com Omega: 2D to 3D conversion none 
http://www.molsoft.com ICM: 2D to 3D conversion none 
http://davapc1.bioch.dundee.ac.uk/programs/prodrg/ Possible 2D to 3D  [317] 
http://bioserv.rpbs.jussieu.fr/Frog.html Frog: a FRee Online druG 3D conformation generator [318] 
http://edetox.ncl.ac.uk/ Find compound properties none 
http://www.eyesopen.com Filter: ADME/tox online none 
http://www.molinspiration.com/ ADME/tox online none 
http://www.molsoft.com/mprop ADME/tox online none 
http://www.chemaxon.com/products.html ADME/tox online none 
http://sw16.im.med.umich.edu/software/xtool/   Xscore : logP computation tool   [319] 
http://www.logp.com/ Compute logP none 
http://preadmet.bmdrc.org/preadmet/index.php  PreADMET is a web-based application for predicting 
ADME data 
none 
http://www.niehs.nih.gov/nct/cebs.htm Chemical Effects in Biological Systems (CEBS) 
knowledge base (application of systems biology to 
ADME/Tox) 
National 
Center for 
Toxicogen-
mics 
(none) 
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Table IV: Some free tools for small ligand docking and SB-VLS 
 
 
 
 
 
 
URLs Short summary Ref. 
http://www.scripps.edu/mb/olson/doc/autodock AutoDock, small molecule docking (rigid receptor although 
some side chains can move, flexible ligand) 
[320] 
http://www.simbiosys.ca/ehits/index.html eHits: small molecule docking (rigid receptor, flexible 
ligand) 
[321] 
http://mgltools.scripps.edu/Members/yongzhao/home
-of-flipdock/ 
FLIPDock: docking flexible ligands into flexible receptors [247] 
http://www.eyesopen.com FRED: small molecule rigid docking tool [322] 
http://www.dddc.ac.cn/tarfisdock/ tarFisDock docks ligands into the proteins targets in PDTD 
(Potential Drug Target Database), and outputs the top 2%, 
5% or 10% candidates ranked by the energy score,  including 
their binding conformations and a table of the related target 
information 
[323] 
http://dock.compbio.ucsf.edu/ DOCK: small molecule docking tool (rigid receptor, flexible 
ligand) 
 
[281] 
http://www.biopharmics.com Surflex: small molecule docking (rigid receptor, flexible 
ligand) 
 
[324, 325] 
http://www.tcd.uni-konstanz.de/research/plants.php Plants: small molecule docking (rigid receptor although 
some side chains can move, flexible ligand) 
 
[326] 
ftp://ftp2.ipc.pku.edu.cn/pub/software PSI-DOCK: small molecule docking (rigid receptor although 
some side chains can move, flexible ligand) 
[327] 
http://ang.cz3.nus.edu.sg/cgi-bin/prog/rune.pl PEARLS: program for energetic analysis of receptor-ligand 
system  
[328] 
http://www.scfbio-iitd.res.in/dock/pardock.jsp 
 
ParDOCK is an all-atom energy based Monte Carlo, rigid 
protein ligand docking tool 
[327] 
http://abcis.cbs.cnrs.fr/kindock/ 
http://abcis.cbs.cnrs.fr/LIGBASE_SERV_WEB/PHP
/simdock.php 
Kindock and Simdock: tool for comparative docking of 
protein kinase ligands and ligand transposition server 
[156] 
http://indyo2.biow.uni-leipzig.de/psoatautodock.html Pso@autodock: a fast flexible molecular docking program 
based on Swarm Intelligence 
[329] 
http://www.bio.ifi.lmu.de/~apostola/index.html GlamDock: a new docking tool that could become available [330] 
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Fig. 1: Schematic overview of the in silico-in vitro drug discovery process 
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Fig. 2: Druggable pocket prediction: The catalytic site of a serine protease is shown 
with a view down the active site. A crystallized small molecule inhibitor is displayed as 
CPK sphere (yellow). The predicted druggable pocket performed with Q-Site finder is in 
navy blue. Several other proposed druggable pockets are highlighted with black arrows 
but not shown to facilitate the reading of the figure. It is known from site directed 
mutagenesis and crystallographic studies that serine proteases interact with other proteins 
in these areas, confirming the overall efficiencies of druggable pocket prediction 
methods. 
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Fig. 3: Examples of protein complexes with a clear druggable pocket at the interface. Top left: 
Thrombin (solid surface with carbon atoms in green, predicted positively charged groups in blue and 
negatively charged red) is crystallized with platelet glycoprotein Ib-alpha (cartoon representation, 
orange) (PDB code 1ook) [331]. Top right, thrombin is removed and the arrow highlights a druggable 
pocket that is more visible in 3D than in a 2D drawing. Bottom left. The Rac1-GTP (cartoon)/p67TPR 
(solid surface) complex (PDB code 1e96) [332]. Bottom right, one partner is removed and a clear 
druggable pocket can be seen at the interface. 
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Fig. 4: Example of in silico-in vitro screening flowchart for PPIs 
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Fig. 5: ADME/Tox guidelines: the ultimate profile that we would like to have for the 
selected compounds. Many of these parameters cannot be predicted accurately in silico 
with currently available methods and our knowledge on many of the steps is sill very 
limited. The term pharmacokinetics (PK) is often used when dealing with ADME 
properties, this is because PK can be defined as the study of the time course of a drug 
within the body and because it incorporates the process of absorption, distribution, 
metabolism and excretion. For the sake of simplification, pharmacodynamics (PD) is 
often summarized as the study of what a drug does to the body, whereas 
pharmacokinetics is the study of what the body does to a drug.  
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Fig. 6: Some possible ways for handling receptor flexibility 
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Fig. 7: Stat3-DNA complex 
The Stat3 monomer structure is shown as a solid surface with the DNA molecule shown 
in light grey and the binding pocket for association with the other monomer and for the 
interaction with drug-like compounds identified after in silico-in vitro screening shown in 
white. The top molecule is from Song et al. [277] and the bottom compound is from 
Siddiquee et al. [275]. 
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  Fig. 8: Antitrypsin 
   The Z mutation is highlighted and so are the so-called β-sheet A and reactive 
   center loop. The allosteric binding pocket is colored white and the best compound 
   identified in that study is the bottom compound that block polymerization. 
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Fig. 9: β-catenin 
The X-ray structure of β-catenin is shown as a solid surface with the pocket selected for 
virtual screening highlighted in white. One compound identified by in silico screening 
followed by biophysical screening is shown. It is not yet fully confirmed if this ligand 
binds to this pocket. 
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Fig. 10: Plant H
+
-ATPase-14-3-3-fusicoccin complex 
SB-VLS was performed on the 14-3-3 protein in order to replace fusicoccin, a small fungal 
toxin known to stabilize the H+-ATPase-14-3-3 protein complex. Only few residues from the 
ATPase are present in this crystal structure while 4 water molecules (not visible in this figure) 
are located near the ligand. The toxin is co-crystallized in a small pocket and interacts with at 
least one residue from the ATPase. The toxin is also drawn to the right to be consistent with 
the other figures. 
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